We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Sara Kenkare-Mitra - Senior Vice President, Development Sciences

Sara Kenkare-Mitra

Senior Vice President, Development Sciences

Years at Genentech
Awards & Honors

I joined Genentech in 1998 as a Pharmacokinetics Scientist and over the years have held various team and leadership roles leading to my current position as Senior Vice President of Development Sciences. In this role, I am responsible for ensuring the successful translation of promising molecule –discoveries from Research into Development and the effective utilization of development sciences during the clinical phases of drug development. In addition, I am a member of the gRED leadership team, the Development Review committee (DRC), the Research Review committee (RRC) and the Early stage portfolio committee (ESPC). I am also an adjunct faculty at UCSF (Department of Bioengineering and therapeutic Sciences) and at the University of Pacific, Stockton.

I am committed to developing treatments for patients that may significantly improve their lives and am excited to be a part of an organization that continues to be on a mission to really shape the future of medicine. I have had the opportunity to see my individual impact on a number of biologics and small molecules and feel fortunate to work with such a talented and diverse group of passionate people.

Featured Publication

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Cancer Res.; 68:(22), (2008).

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.